Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chronic Lymphocytic Leukemia (3 trials), Non Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
- Main trialPhase 3
- “This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.”In the company’s words, NCT02612311 on ClinicalTrials.gov
Other drugs for Chronic Lymphocytic Leukemia
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- VenetoclaxAbbVie · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 3
- AcalabrutinibAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 22 Feb 2023 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | |
| Phase 2Terminated | 25 May 2022 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | |
| Phase 1Completed | Feb 2018 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026